EGFR and Skin rash: On the other hand, median PFS and OS were not significantly longer in patients with skin rash as an adverse event of EGFR-TKIs than in those without skin rash (PFS 508 [95% CI 411–647] days vs. 382 [95% CI 328–731] days, p = 0.47; OS 1216 [95% CI 843–2825] days vs. 1428 [95% CI 776–2448] days, p = 0.68) (Supplementary Fig. S1).